CRBN在免疫调节剂治疗多发性骨髓瘤中的研究进展

Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma

多发性骨髓瘤(multiple myeloma,MM)是浆细胞恶性克隆增殖性疾病,目前仍不能治愈。近年来,靶向药物免疫调节剂(immunomodulatory drugs,IMiD)的广泛使用,使得MM的治疗取得了很大进展,极大程度地提高了完全缓解率,延长了患者的总生存期。研究证实,CRBN(cereblon)是IMiD发挥抗骨髓瘤效应的直接作用靶点,其表达高低与IMiD的治疗疗效及多发性骨髓瘤患者的预后相关。CRBN的发现不仅深化了对IMiD分子药理机制的认识,也为寻求新的治疗靶点,研究新的治疗策略提供了理论基础。本文就CRBN与IMiD治疗MM的疗效及作用机制的研究进展进行综述,讨论的具体问题包括CRBN的发现,CRBN与IMiD的治疗疗效和CRBN在IMiD治疗MM中的作用机制等。

Multiple myeloma is a plasma cell malignant clone proliferation diseases and has been remained incurable.In the resent years,the widespread application of immunomodulatory drugs（IMiD） have made a great progress in the treatment of multiple myeloma,greatly improved the complete remission rate and prolonged the overall survival of MM patients.According to recent researches,CRBN（cereblon） plays an important role in mediating anti-myeloma effects of IMiD,and its expression correlated with the effect of IMiD treatment and the prognosis of multiple myeloma.The discovery of CRBN not only deepened the understanding the molecular pharmacological mechanisms of IMiD,but also provide new insights into the novel therapeutic targets and therapeutic strategies for myeloma.This review focuses on the research advances of effectiveness and related mechanisms of CRBN and IMiD for MM,the concrete problems discussing in this review are discover of CRBN,therapeutic effect of CRBN and IMiD,mechnism of CRBN in IMiD treatment for MM,and so on.